FI107737B - Plasmid för att uttrycka en tyrosinhydroxylasgen i hjärnan - Google Patents

Plasmid för att uttrycka en tyrosinhydroxylasgen i hjärnan Download PDF

Info

Publication number
FI107737B
FI107737B FI992771A FI19992771A FI107737B FI 107737 B FI107737 B FI 107737B FI 992771 A FI992771 A FI 992771A FI 19992771 A FI19992771 A FI 19992771A FI 107737 B FI107737 B FI 107737B
Authority
FI
Finland
Prior art keywords
expression
plasmid
brain
disease
gene
Prior art date
Application number
FI992771A
Other languages
English (en)
Finnish (fi)
Other versions
FI19992771A (sv
Inventor
Atso Raasmaja
Mart Ustav
Pekka T Maennistoe
Original Assignee
Atso Raasmaja
Mart Ustav
Pekka T Maennistoe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atso Raasmaja, Mart Ustav, Pekka T Maennistoe filed Critical Atso Raasmaja
Priority to FI992771A priority Critical patent/FI107737B/sv
Priority to AU25186/01A priority patent/AU2518601A/en
Priority to PCT/FI2000/001140 priority patent/WO2001048232A1/en
Publication of FI19992771A publication Critical patent/FI19992771A/sv
Application granted granted Critical
Publication of FI107737B publication Critical patent/FI107737B/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/16—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with reduced pteridine as one donor, and incorporation of one atom of oxygen (1.14.16)
    • C12Y114/16002—Tyrosine 3-monooxygenase (1.14.16.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/20043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/60—Vectors comprising a special origin of replication system from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA

Claims (6)

1. Expressionsplasmid av typ-1 bovin papillomavirus (Bovine Papilloma Virus Type-1, BPV-1), som innehäller
5. El- och E2-gener av papillomavirus för en stabil extrakromosomal replikation, - ett minimal origin-element (MO) av papillomavirusreplikationen, - ett minikxomosomalt upprätthällningselement (MME), - en nukleotidsekvens, som kodar för en tyrosinhydroxylasenzym (ΤΗ).
2. Expressionsplasmid enligt patentkravet 1, som ytterligare innehäller regleringsregioner för att kontrollera expression och transkription.
3. Expressionsplasmid enligt patentkravet 2, i vilken regleringsregionema innehäller promotorer, som leder expression av TH i cellema. 15
4. Expressionsplasmid enligt patentkravet 2, i vilken regleringsregionema innehäller - en uppströms-regleringsregion av BPV-1 (URR) och - en tymidinkinas (Tk) promotor.
5. Användning av en expressionsplasmid enligt nagot av patentkraven 1-4 vid framställning av ett läkemedelspreparat för genterapeutisk behandling av neurala eller nonneurala sjukdomar.
*· • · « ·· ♦ · • *·· 6. Användning enligt patentkravet 5, kännetecknad därav, att sjukdomen är Parkinsons • · *.* 25 sjukdom. ·· φ m · 4 • · * • ♦ · ♦ * · * ^ · • · ··♦ 4 · 4 ··♦ • · ··· • 4 • · #·· ·· 4 4 • ·· 4 4 4
FI992771A 1999-12-23 1999-12-23 Plasmid för att uttrycka en tyrosinhydroxylasgen i hjärnan FI107737B (sv)

Priority Applications (3)

Application Number Priority Date Filing Date Title
FI992771A FI107737B (sv) 1999-12-23 1999-12-23 Plasmid för att uttrycka en tyrosinhydroxylasgen i hjärnan
AU25186/01A AU2518601A (en) 1999-12-23 2000-12-22 A plasmid for the expression of a therapeutic gene in a tissue
PCT/FI2000/001140 WO2001048232A1 (en) 1999-12-23 2000-12-22 A plasmid for the expression of a therapeutic gene in a tissue

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI992771 1999-12-23
FI992771A FI107737B (sv) 1999-12-23 1999-12-23 Plasmid för att uttrycka en tyrosinhydroxylasgen i hjärnan

Publications (2)

Publication Number Publication Date
FI19992771A FI19992771A (sv) 2001-06-24
FI107737B true FI107737B (sv) 2001-09-28

Family

ID=8555804

Family Applications (1)

Application Number Title Priority Date Filing Date
FI992771A FI107737B (sv) 1999-12-23 1999-12-23 Plasmid för att uttrycka en tyrosinhydroxylasgen i hjärnan

Country Status (3)

Country Link
AU (1) AU2518601A (sv)
FI (1) FI107737B (sv)
WO (1) WO2001048232A1 (sv)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674703A (en) * 1992-12-02 1997-10-07 Woo; Savio L. C. Episomal vector systems and related methods
EP0870047B1 (en) * 1995-12-29 2008-08-06 FIT Biotech Oyj Plc Episomal vector and uses thereof
AU1275299A (en) * 1997-10-23 1999-05-10 Uab Research Foundation Human papillomavirus vectors for the episomal transduction of host cells and method of making same
FI105105B (sv) * 1998-02-27 2000-06-15 Finnish Immunotechnology Ltd O Självreplikerande DNA-vektor för immunisering mot HIV

Also Published As

Publication number Publication date
AU2518601A (en) 2001-07-09
FI19992771A (sv) 2001-06-24
WO2001048232A1 (en) 2001-07-05

Similar Documents

Publication Publication Date Title
JP5108797B2 (ja) 色素上皮誘導因子：ｐｅｄｆ遺伝子の特性評価、ゲノム構成および配列
Klugmann et al. AAV-mediated hippocampal expression of short and long Homer 1 proteins differentially affect cognition and seizure activity in adult rats
Wolff et al. Grafting fibroblasts genetically modified to produce L-dopa in a rat model of Parkinson disease.
Lemkine et al. Adult neural stem cell cycling in vivo requires thyroid hormone and its alpha receptor
US5851832A (en) In vitro growth and proliferation of multipotent neural stem cells and their progeny
Thompson et al. Conditionally immortalized cell lines, engineered to produce and release GABA, modulate the development of behavioral seizures
NO327597B1 (no) Modulatorer for vevsregenerering
Park et al. ATF3 negatively regulates adiponectin receptor 1 expression
AU777187B2 (en) Novel mitogenic regulators
US5998188A (en) Mitogen activated protein kinase phosphatase cDNAS and their biologically active expression products
EP1107797A2 (en) Hypoxia regulated genes
AU755251B2 (en) Compositions and methods for sensitizing and inhibiting growth of human tumor cells
CN108610409B (zh) Etv5在制备预防或治疗肥胖症及相关代谢性疾病药物中的应用
FI107737B (sv) Plasmid för att uttrycka en tyrosinhydroxylasgen i hjärnan
Barkats et al. Intrastriatal grafts of embryonic mesencephalic rat neurons genetically modified using an adenovirus encoding human Cu/Zn superoxide dismutase
Ikari et al. Adenovirus-mediated gene transfer of dopamine D2 receptor cDNA into rat striatum
JP2008530029A (ja) 神経保護剤およびそれらの使用方法
EP2059598B1 (en) Compositions and methods for modulating ampa receptor-mediated excitotoxicity
US8124393B2 (en) Compositions and methods for inducing or inhibiting activities of selected human cells
JP3761152B2 (ja) ヒトグリア細胞株由来神経栄養因子プロモーター、該プロモーターを含むベクター、および該プロモーターによる化合物のスクリーニング方法
GB2400103A (en) Cell lines expressing VGSC, Nav1.8
Sui et al. Neuroprotective roles of HAX-1 in ischemic neuronal injury
KR20140030934A (ko) 퍼옥시레독신 2 융합단백질을 함유하는 뇌 허혈손상 예방 및 치료용 약학 조성물
WO2006123644A1 (ja) 低酸素ストレス応答に関与するInt6タンパク質、およびその利用
WO1994001135A1 (en) Method of producing genetically modified astrocytes and uses thereof

Legal Events

Date Code Title Description
MA Patent expired